Skip to content

Epzicom Brand Abacavir-Lamivudine QD

  • Chad Cipiti

The Difference Between Drugs and New Drugs By Rob Camp August 2004 FDA announced approvals in early August of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents for the treatment of HIV-1 infection. FDCs are…

Read more

Two Out of Three Ain’t Bad

  • Chad Cipiti
In early August, FDA announced approvals of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents in the treatment of HIV-1 infection: GlaxoSmithKline's Epzicom® (abacavir/lamivudine) and Gilead Sciences, Inc.'s Truvada® (tenofovir disoproxil/emtricitabine).
Read more

NIH Hearing on Norvir 400% Price Increase, 2004

  • Chad Cipiti

By Rob Camp Edited by Jen Curry AIDS Treatment Activists Coalition (ATAC) On Tuesday, May 25, 2004, the National Institutes of Health (NIH) hosted a public meeting to seek comment from invited individuals, organizations, and other stakeholders on the use…

Read more

2004 Pipeline Report

  • Chad Cipiti

February 2004 By Rob Camp Not so fast! Where's my pipeline? Pipelines are almost as delicate and fragile as the ecosystems they go trampling through. Oft times the way to get from the beginning to the end is not a…

Read more

TAG Postition Paper on Fosamprenavir Approval

  • Chad Cipiti

And speaking of boosting… By Rob Camp and Heidi Nass December 2003 Executive Summary FDA granted accelerated approval to Agenerase® brand amprenavir (NDA 21-007 and NDA 21-039) in April 1999. 908 allows us an opportunity to get an easier-to-use drug…

Read more

2003 Pipeline Report

  • Chad Cipiti

By Rob Camp The pipeline is bursting, with at least the following compounds twinkling in the eyes of scientists around the globe. It is by no means a full list, but those substances in red were presented at the recent…

Read more
Back To Top